Close

Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The Ultimate Pain Relief Guide: Proven Tips to Manage Discomfort Naturally

Pain is something that we all go through somehow...

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

Ajinomoto Bio-Pharma Services Cold Chain Technologies Partners with B Medical Systems , a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufacturing.

This agreement expands the scope of Aji Bio-Pharma’s service offerings to AstraZeneca to include aseptic fill finish services at its San Diego, California facility, in addition to small molecule manufacturing services proceeding in Belgium. “We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings,” said Magnus Busch, Global Account Manager, Ajinomoto Bio-Pharma Services. “Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients.”

About Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our client’s needs.

Latest stories